ACTH (1-39)

Overview

ACTH (1-39), or corticotropin, is the complete 39-residue melanocortin peptide released from the anterior pituitary after proopiomelanocortin (POMC) processing. It is the primary secretagogue of the hypothalamic-pituitary-adrenal (HPA) axis: binding the melanocortin-2 receptor on the adrenal cortex drives steroidogenesis and the release of cortisol and other glucocorticoids. Because essentially all of the receptor-activating potency lives in the first 24 residues, ACTH (1-39) research overlaps with the shorter ACTH (1-24)/tetracosactide tool compounds, but the full-length sequence remains the reference form for adrenal-responsiveness and POMC-processing studies. PeptideXpo supplies human-sequence ACTH (1-39) as a lyophilized acetate salt at ≥ 98% HPLC. The peptide is sensitive to oxidation at its methionine residues and to surface adsorption at the low working concentrations typical of adrenal-cell assays, so buyers should reconstitute in a low-binding or carrier-protein vehicle and aliquot to avoid freeze-thaw cycling. Porcine and rat/mouse sequences differ from the human form in the C-terminal region — specify the species context whenever the readout depends on receptor- or epitope-species matching. Supplied as a research reference material only.

Specifications

CAS

12279-41-3

Molecular Formula

C207H308N56O58S

Molecular Weight

4541.07 Da

Sequence

H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 98%

Strength

5 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 15 minutes

MOQ

On request

Lead time

7–14 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Ghaddhab C, Vuissoz JM, Deladoëy J. From Bioinactive ACTH to ACTH Antagonist: The Clinical Perspective. Front Endocrinol (Lausanne). 2017;8:17.
2. Chen M, Aprahamian CJ, Kesterson RA Jr, Harmon CM, Yang Y. Molecular identification of melanocortin-2 receptor responsible for ligand binding and signaling. Biochemistry. 2007;46(40):11389-11397.
3. Chakraborty R, Mehta A, Nair N, Nemer L, Jain R, Joshi H, Raina R. ACTH Treatment for Management of Nephrotic Syndrome: A Systematic Review and Reappraisal. Int J Nephrol. 2020;2020:2597079.
4. Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol Dial Transplant. 2014;29(8):1570-1577.
5. Duchowny MS, Chopra I, Niewoehner J, Wan GJ, Devine B. A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms. J Health Econ Outcomes Res. 2021;8(1):1-9.
6. Kaplan J, Miller T, Baker M, Due B, Zhao E. A prospective observational registry of repository corticotropin injection (Acthar Gel) for the treatment of multiple sclerosis relapse. Front Neurol. 2020;11:598496.

Frequently asked questions